Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: Membership privileges

    Brexit of brains Strategy Membership privileges Accessibility of EU research funds through Horizon 2020 depends on a country's relationship to the EU. For Member States, it is an integral part of the EU membership …

    Published on 7/21/2016
  • Figure: Shepherd's pie

    Brexit of brains Strategy Shepherd's pie A breakdown of the EU's sources of funding for research, development and innovation, including the amount received by the U.K. during the Seventh Framework Programme (FP7) …

    Published on 7/21/2016
  • Brexit of brains

    Research brain drain dominates post-Brexit fears in U.K.

    Although the U.K.'s life sciences sector anticipates Brexit will hit academia worse than industry, a research brain drain could have repercussions for the whole ecosystem.

    Published on 7/21/2016
  • Figure: Six is better than one

    Apogenix's hex on TNF Product R&D Six is better than one Apogenix AG has developed a platform for designing fusion protein agonists of TNF family receptors that stimulate a high level of receptor signaling by …

    Published on 7/14/2016
  • Table: BioCentury Product Profile

    Apogenix's hex on TNF Product R&D BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Fusion protein agonists of TNF superfamily receptors designed using the Hexavalent TNF Superfamily…

    Published on 7/14/2016
  • Apogenix's hex on TNF

    How Apogenix is using fusion proteins to tackle immuno-oncology targets

    Apogenix is designing hexavalent TNF receptor ligands to compete with agonist mAbs in the clinic based on better potency from a more natural mode of receptor activation.

    Published on 7/14/2016
  • Figure: Triggering AD

    AChE revisited Targets & Mechanisms Triggering AD Neuro-Bio Ltd. has identified a peptide derived from AChE that is overexpressed in the brain centers that degenerate first in Alzheimer's disease (AD), and has …

    Published on 6/30/2016
  • Table: BioCentury Product Profile

    AChE revisited Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A compound that inhibits binding of an AChE-derived peptide to CHRNA7 Concept Prevent …

    Published on 6/30/2016
  • AChE revisited

    Why Neuro-Bio thinks it's time to revisit the role of AChE in AD

    With a new take on an old target, Neuro-Bio believes a developmental form of AChE holds the key to slowing neurodegeneration in Alzheimer's disease.

    Published on 6/30/2016
  • What GWAS will be

    Two studies help find which GWAS hits actually matter

    With a new way to identify the few functional genetic variants from thousands of hits, two groups have taken GWAS to the next level.

    Published on 6/23/2016
  • Figure: Massive screen of small changes

    What GWAS will be Tools & Techniques Massive screen of small changes Two groups from the Broad Institute of MIT and Harvard have published a pair of studies in Cell showing a massively parallel reporter assay (MPRA…

    Published on 6/23/2016
  • Figure: Axis of diabetes

    The Finnish connection Targets & Mechanisms Axis of diabetes An international research group has found that differences between the standards of living in Russia, Estonia and Finland are linked to differences in …

    Published on 6/16/2016
  • Figure: Battle of the bugs

    The Finnish connection Targets & Mechanisms Battle of the bugs In a study in Cell, an international consortium of researchers showed that susceptibility to Type I diabetes was affected by regional differences in …

    Published on 6/16/2016
  • The Finnish connection

    The microbiome link between Finnish children and Type I diabetes

    By comparing microbiomes of Finnish, Russian and Estonian infants, an international consortium has found a molecular link between Type I diabetes and Bacteroides bacteria.

    Published on 6/16/2016
  • Sanofi's post-reconstruction era

    How research head Yong-Jun Liu is capstone to Zerhouni's R&D overhaul at Sanofi

    Immunology guru Yong-Jun Liu has a mandate to build a biology-based R&D engine at Sanofi and help the pharma make up for lost time in immuno-oncology.

    Published on 6/9/2016
  • Table: Academic Angles

    Sanofi's post-reconstruction era Strategy Academic Angles Select academic institutions involved in recent research collaborations with Sanofi (Euronext:SAN; NYSE:SNY). (A) indicates expired or inactive …

    Published on 6/9/2016
  • Table: Preclinical Peek

    Sanofi's post-reconstruction era Strategy Preclinical Peek Although Sanofi (Euronext:SAN; NYSE:SNY) isn't making its complete preclinical pipeline public, the pharma has disclosed several preclinical programs, some…

    Published on 6/9/2016
  • Digital Preclinical

    How Vium is automating data collection to overhaul in vivo research practices

    Vium is using its techie founders' Silicon Valley know-how to overhaul animal research and increase reproducibility in preclinical studies.

    Published on 6/2/2016
  • Dissociating ketamine

    An NMDA receptor-independent ketamine metabolite might bypass the drug's side effects

    The discovery of a ketamine metabolite that alleviates depression without causing psychedelic effects could upend a major hypothesis about the drug's action.

    Published on 5/26/2016
  • Figure: Converting ketamine

    Dissociating ketamine Targets & Mechanisms Converting ketamine Collaborators at NIH and the University of Maryland used the structures of the (R) and (S) enantiomers of ketamine and its hydroxynorketamine (HNK) …

    Published on 5/26/2016
  • Figure: Ketamine mimics

    Dissociating ketamine Targets & Mechanisms Ketamine mimics The anesthetic ketamine is an NMDA receptor antagonist known to have antidepressant activity, but it also causes severe psychedelic side effects. In a …

    Published on 5/26/2016
  • Table: BioCentury Product Profile

    Dissociating ketamine Targets & Mechanisms BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product (2R,6R)-hydroxynorketamine Concept A ketamine metabolite that recapitulates the drug's …

    Published on 5/26/2016
  • Box: Set to launch

    Mind the gap Strategy Set to launch The U.K. government's technology strategy board, renamed Innovate U.K., has created a Catapult Programme composed of 11 centers, each focused on accelerating a different …

    Published on 5/19/2016
  • Mind the gap

    U.K. keeps calm and boosts translational science

    The U.K. is boosting biotech with a slew of new investments and initiatives to help universities spin out discoveries rather than primarily license them to pharmas.

    Published on 5/19/2016
  • Modeling with interference

    How marrying CRISPRi with iPS can produce better disease models

    By marrying CRISPRi with iPS cells, a UCSF team has created a scalable, widely applicable form of genetic knockdown for more - and better - models of disease.

    Published on 5/12/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993